新しい切除された乳癌腫瘍のテラヘルツ画像化と特性化プロトコル

Executive Industry Relevance

Terahertz imaging provides a non-ionizing, label-free method to assess surgical margins in solid tumors, addressing a key unmet need in oncology drug development and preclinical validation. By enabling rapid differentiation between malignant and healthy tissues based on intrinsic optical properties, the technique supports mechanistic de-risking of therapeutic candidates and improves predictive confidence in preclinical models. Its applicability to freshly excised tumors facilitates translational continuity from discovery through preclinical evaluation, reducing late-stage attrition due to inadequate target engagement or off-target effects.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of tumor heterogeneity and functional validation of targets in native tissue context without fixation artifacts.
• Operational Value: Supports rapid screening of genetically engineered models for target-dependent phenotypic changes in tumor margins.

Screening & Assay Development

• Scientific Value: Provides quantitative, label-free readouts of refractive index and absorption coefficient as biomarkers of tumor phenotype.
• Operational Value: Delivers reproducible, high-resolution imaging data suitable for assay standardization across compound screening campaigns.

Translational & Preclinical Research

• Scientific Value: Facilitates correlation of imaging phenotypes with histopathological and molecular endpoints for target validation.
• Operational Value: Enables longitudinal monitoring of tumor response in orthotopic and patient-derived xenograft models without tissue destruction.

Pipeline & Workflow Integration

The method integrates into the discovery continuum by supporting hypothesis testing in early biology, enabling quantitative assay readouts for screening, and providing translational imaging biomarkers for preclinical continuity.

• Discovery Biology: Allows non-destructive interrogation of tumor architecture and target expression patterns in fresh tissue.
• Screening: Generates standardized, quantitative optical property maps for evaluating compound effects on tumor morphology.
• Analytics: Yields frequency-dependent absorption and refractive index metrics that enable statistical comparison across experimental conditions.
• Translational Research: Bridges in vitro findings to intact tumor phenotypes, supporting go/no-go decisions based on margin status and invasiveness.
• Enterprise Reuse: Represents a platform capability applicable across solid tumor indications, maximizing ROI on imaging infrastructure.

Operational & Enterprise Impact

• Scientific Value: Enhances target validation confidence by reducing mechanistic ambiguity in tumor-stroma interactions.
• Operational Value: Ensures reproducibility through standardized tissue handling and stage balancing protocols.
• Strategic Value: Improves risk-adjusted decision-making by providing early, objective metrics of tumor invasiveness and treatment response.
• Portfolio Impact: Supports prioritization of candidates with favorable margin modulation profiles, reducing late-stage failure risk.

Implementation Considerations

• Requires expertise in terahertz optics, tissue handling, and spectroscopic data analysis.
• Depends on access to terahertz time-domain spectroscopy systems with scanning stages and polystyrene sample platforms.
• Necessitates standardized protocols for tumor preparation, including fluid removal and air bubble minimization, to ensure data quality.
• Involves adaptation considerations for varying tumor sizes, densities, and stromal compositions across model systems.
• Includes practical limitations related to sample dehydration over time and signal attenuation in highly hydrated or necrotic tissues.

Biopharma FAQs